Clinical-Stage Biotech Committed to Advancing Novel Therapies for Rare Endocrine Disorders

Spruce Biosciences is a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders. Our team has extensive expertise in endocrinology and orphan drug development and our lead product candidate, Tildacerfont (SPR001), has the potential to be the first FDA-approved therapy for congenital adrenal hyperplasia (CAH), a rare endocrine disease. We are headquartered in San Francisco and have raised a total of $28M.

Or lead program, SPR001, is currently in Phase 2 clinical trials for CAH. For more information on CAH please visit our patient resources section. If you are a patient interested in learning more about our clinical trials and may be eligible to participate, please visit our clinical trials page.

Leadership+ Board of Directors + Investors +

Congenital Adrenal Hyperplasia Clinical Trials 2019

Spruce also has ongoing collaborations with the National Institutes of Health (NIH) for longer duration study of the safety and efficacy of tildacerfont in adults 18+.
Learn More
 
If you are age 12+ and diagnosed with Congenital Adrenal Hyperplasia, we invite you to join our Natural History Study and Registry.

The CAH Natural History Study's mission is to learn more about CAH so researchers can work to improve the quality of life and the health of individuals with CAH, and to provide hope through the promise of new treatments.

Learn More

Spruce Biosciences is a clinical-stage biotechnology company developing novel therapies to better serve patients with rare endocrine disorders. Our team has extensive experience with managing patients with rare endocrine diseases as well as developing novel therapeutics to treat patients with unmet needs. As a team, we are committed to transforming the quality of life for patients who have been underserved by scientific innovation.